We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+51.2%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$3.01B
AUM Growth
+$676M
Cap. Flow
-$150M
Cap. Flow %
-4.98%
Top 10 Hldgs %
75.26%
Holding
119
New
16
Increased
18
Reduced
26
Closed
23

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$54.2M
2
SRRK icon
Scholar Rock
SRRK
+$27.3M
3
ARWR icon
Arrowhead Research
ARWR
+$27.2M
4
PRTA icon
Prothena Corp
PRTA
+$19.3M
5
KRRO icon
Korro Bio
KRRO
+$13.8M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$114M
2
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$46.9M
3
IMGN
Immunogen Inc
IMGN
+$24M
4
FOLD
Amicus Therapeutics
FOLD
+$23.1M
5
RVMD icon
Revolution Medicines
RVMD
+$20M

Sector Composition

Rank Sector Weight
1 Healthcare 50.36%
2 Consumer Discretionary 46.45%
3 Technology 0.44%
4 Real Estate 0.13%
5 Communication Services 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DYN icon
26
Dyne Therapeutics
DYN
$4.21B
$16.2M 0.54%
1,217,960
+402,875
+49% +$3.94M
WVE icon
27
Wave Life Sciences
WVE
$1.12B
$15.2M 0.5%
3,007,400
+1,007,400
+50% +$5.38M
SE icon
28
Sea Limited
SE
$66.1B
$15.1M 0.5%
372,000
-25,000
-6% -$1.02M
HARP
29
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$14.8M 0.49%
1,304,127
+1,204,127
+1,204% +$9.46M
AGEN
30
Agenus
AGEN
$274M
$12.9M 0.43%
781,562
– –
NTRA icon
31
Natera
NTRA
$36.4B
$12.5M 0.42%
200,000
– –
ROIV icon
32
Roivant Sciences
ROIV
$24.1B
$11.2M 0.37%
1,000,000
– –
GOSS icon
33
Gossamer Bio
GOSS
$97.1M
$11M 0.37%
12,058,968
+5,659,149
+88% +$4.18M
SDGR icon
34
Schrodinger
SDGR
$1.12B
$10.7M 0.36%
300,000
-200,000
-40% -$5.8M
ERAS icon
35
Erasca
ERAS
$6.06B
$10.1M 0.33%
4,721,194
– –
FUSN
36
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$9.66M 0.32%
1,005,500
-719,500
-42% -$3.5M
SEER icon
37
Seer Inc
SEER
$115M
$9.21M 0.31%
4,750,000
– –
LXEO icon
38
Lexeo Therapeutics
LXEO
$340M
$8.1M 0.27%
+603,435
New +$7.5M
CNTA
39
DELISTED
Centessa Pharmaceuticals
CNTA
$8.06M 0.27%
+1,012,500
New +$6.79M
OVID icon
40
Ovid Therapeutics
OVID
$427M
$8.05M 0.27%
2,500,000
– –
CBAY
41
DELISTED
Cymabay Therapeutics
CBAY
$7.17M 0.24%
+303,600
New +$5.41M
TSM icon
42
TSMC
TSM
$1.96T
$7.07M 0.24%
67,999
-34,700
-34% -$3.31M
TSHA icon
43
Taysha Gene Therapies
TSHA
$1.55B
$6.48M 0.22%
3,663,104
– –
RNAC icon
44
Cartesian Therapeutics
RNAC
$223M
$6.3M 0.21%
304,555
– –
VIGL
45
DELISTED
Vigil Neuroscience
VIGL
$6.12M 0.2%
1,811,191
-96,944
-5% -$499K
ARWR icon
46
CALL
Arrowhead Research
ARWR
$12.2B
$6.12M 0.2%
+200,000
New +$5.31M
BDTX icon
47
Black Diamond Therapeutics
BDTX
$95.7M
$5.75M 0.19%
2,046,517
– –
SLDB icon
48
Solid Biosciences
SLDB
$796M
$5.58M 0.19%
909,219
– –
VOR icon
49
Vor Biopharma
VOR
$1.06B
$5.28M 0.18%
117,371
-17,030
-13% -$703K
RPTX
50
DELISTED
Repare Therapeutics
RPTX
$5.11M 0.17%
700,000
– –
1
2
3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q4 2023 Portfolio in Review

As of Q4 2023, Artal Group held 119 positions worth $3.01B, up 29% from $2.33B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Artal Group withdrew a net $150M in Q4 2023, closing 23 positions and reducing 26 holdings. Its most notable exit was Mirati Therapeutics, Inc. Common Stock, an estimated $114M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, down from 54% a quarter earlier, followed by Consumer Discretionary and Technology.

Against the trend, Artal Group opened a new position in argenx worth $44.3M.

  • Artal Group's largest Q4 2023 buy was argenx: 116,388 shares worth $44.3M.
  • Artal Group added most to Scholar Rock in Q4 2023, an estimated $27.3M increase.
  • Artal Group's biggest Q4 2023 reduction was Cerevel Therapeutics Holdings, Inc. Common Stock, cutting an estimated $46.9M.
  • Artal Group fully exited Mirati Therapeutics, Inc. Common Stock in Q4 2023, selling an estimated $114M.
  • Artal Group's ten largest holdings make up 75% of its $3.01B portfolio in Q4 2023.
  • Artal Group opened 16 new positions and closed 23 in Q4 2023.
  • Artal Group's portfolio value rose 29% quarter-over-quarter to $3.01B.

Based on Artal Group's 13F filing for Q4 2023, filed 9 Feb 2024.